Our proprietary AI Workbench is designed for data-driven prediction, positive feedback loops, and exponential growth. It enables us to identify leads for over 50% of the novel targets we select, and to do so quickly. This is a game changer.
In 2018, our proprietary AI Workbench unlocked our first targets in which RNA splicing was the defect and the mechanism for correction. Our AI Workbench 2.0, released in Spring 2020, expanded the number of mechanisms for increased expression. This work generated over 10 program opportunities for internal and partnered development.
We are currently developing AI Workbench 3.0, which will expand the number of mechanisms and genetic variants we can pursue. This includes expanding into more complex genetic diseases. As genetic targets are less understood in complex genetic disease, the AI Workbench will play an even greater role in identifying novel targets, as well as therapies, to modulate disease. We are now pursuing these programs internally and through partnerships.